Search

Treatment of acute lymphoblastic leukemia by activation of patient's immune cells by a bispecific antibody.

 

Abstract S722
Acute lymphoblastic leukemia  (ALL) is a rare type of blood cancer which is mainly treated by intensive chemotherapy.

Read more

Practical information

When do the meetings take place?
CRTH 2025 timeline is as follows:

Workshop 1: Tuesday, February 4 – Saturday, February 8, 2025
EHA2025 Congress: Thursday, June 12 – Sunday, June 15, 2025
> CRTH Congress session date TBC.

Read more

EHA-ECL led statement calls for protection of the Hospital Exemption

The hospital exemption (HE) is a vital provision within the EU's pharmaceutical legislation, currently subject to a revision.

Read more

EHA-SWG Scientific Meeting on Immunotherapy for Hematological Disorders

EHA and the Scientific Working Group on Immunotherapy for Hematological Disorders are happy to announce the redesigned fully virtual meeting program to meet the needs of hematologists and immunologists in these challenging times.

Read more

EHA & ERN-EuroBloodNet Spotlight on Hypereosinophilic Syndrome Webinars

An accredited European online educational program for health professionals, organized by EHA and ERN-EuroBloodNet. DatesThe sessions will take place on :

Monday, April 15, 2024 at 17:00 (CEST). Monday, May 13, 2024 at 17:00 (CEST).

Read more

EU funding calls for hematology

Horizon Europe
European partnership for pandemic preparedness (November 26, 2024)
Implementation research for management of multiple long-term conditions in the context of non-communicable diseases (Global Alliance for Chronic Diseases - GACD) (deadline: November 26, 2024)
MSCA Doctoral Networks 2024 (deadline: November 27, 2024)
MSCA…

Read more

Multiple Myeloma: EHA-ESMO Clinical Practice Guidelines for Diagnosis, Treatment, and Follow-up

These Guidelines were developed by the European Hematology Association (EHA) and European Society for Medical Oncology (ESMO). The 2 societies nominated authors to write the guidelines as well as reviewers to comment on them.

Read more